A single failed shipment in the cell and gene supply chain does not mean a refund or a reorder. It means a patient loses their only manufactured dose of a therapy that took weeks to produce from their own cells. That is the reality every sponsor, CDMO, and hospital pharmacy is dealing with when they hand a cryopreserved bag of CAR-T cells or a viral vector shipment to a courier. If you are reading this, you are probably past the research stage. You know cell and gene logistics is different from regular pharma freight, and you are trying to figure out which provider can actually handle it without turning your shipment into a case study in what went wrong.
This guide walks through what a serious cell and gene supply chain partner needs to bring to the table, the standards they must meet, and the specific capabilities that separate a general cold chain courier from one built for advanced therapies.
What the Cell and Gene Supply Chain Actually Covers
The cell and gene supply chain is the full sequence of steps that move a living or genetically modified biological product from collection to infusion. For autologous therapies, that starts with apheresis at a clinical site, continues through cryopreservation, transport to a manufacturing facility, processing, and then a return trip back to the same patient. For allogeneic therapies and viral vectors, the chain runs from manufacturing site to hospital or clinic, often across borders.
Every one of these steps carries risk that does not exist in traditional pharmaceutical distribution. A vial of insulin that drifts a few degrees off spec might lose potency. A cryopreserved cell therapy product that warms even briefly outside its validated range can become unusable, and because many of these products are made from a specific patient’s own cells, there is no replacement batch sitting in a warehouse.
Our <a href=”https://stccouriers.in/solutions/cell-and-gene-supply-chain/”>cell and gene supply chain</a> service was built around this exact problem, treating each shipment as a one-of-one event rather than a routine parcel.
Why This Supply Chain Behaves Differently From Standard Pharma Logistics
Most pharmaceutical logistics providers know how to hold a shipment at 2°C to 8°C. That is a solved problem. Cell and gene products introduce three layers of difficulty that standard cold chain providers were never built to manage.
Ultra-Low and Cryogenic Temperature Ranges
Depending on the product, shipments may need to stay anywhere from -20°C down to -196°C in vapor-phase liquid nitrogen. Cryopreserved cell therapies typically sit at the coldest end of that range, while some gene therapy intermediates ship frozen between -65°C and -80°C. A courier that only operates refrigerated trucks and dry ice coolers simply cannot serve this market. Passive shippers rated for cryogenic transport, backed by validated thermal performance data, are non-negotiable.
Chain of Identity, Not Just Chain of Custody
Standard pharma shipments need chain of custody, a record of who held the product and when. Autologous cell therapies need chain of identity as well, meaning the exact patient-specific material must be tracked and matched at every single handoff, with zero tolerance for mix-ups. A courier that treats this as an afterthought is not equipped for the category.
Overlapping Regulatory Frameworks
A single shipment can sit under FDA 21 CFR Part 1271 governing human cells and tissue-based products, IATA Dangerous Goods Regulations if the material is classified as a biological substance, and Good Distribution Practice rules in the destination country, all at once. These frameworks do not apply one after another. They apply simultaneously, and a logistics partner needs systems built to satisfy all of them on the same shipment.
The Real Cost of a Broken Link
It helps to be direct about what failure looks like here. A temperature excursion on a CAR-T shipment can mean the patient restarts apheresis and waits weeks for a new manufacturing slot, assuming their disease allows for that delay. A misrouted shipment crossing a border without the right permits can sit in customs long enough to exceed the product’s validated shipping window. A documentation gap discovered during an audit can jeopardize a clinical trial site’s certification.
None of these are hypothetical. They are the reasons manufacturers and hospital systems are increasingly selective about who touches their cell and gene shipments, and why the vetting process for a logistics partner now looks a lot like vetting a manufacturing vendor. If your organization is running <a href=”https://stccouriers.in/solutions/clinical-trial-logistics/”>clinical trial logistics</a> alongside commercial supply, the stakes multiply, since a single courier failure can affect both a patient outcome and trial data integrity.
The Regulatory Standards Governing This Category
Any provider you evaluate should be able to speak fluently about the following, without needing to look it up mid-conversation.
FDA 21 CFR Part 1271 governs human cells, tissues, and cellular and tissue-based products in the United States, setting donor eligibility, current good tissue practice, and traceability requirements that extend into how these products move between facilities, as detailed directly by the <a href=”https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271″ target=”_blank” rel=”noopener”>Electronic Code of Federal Regulations</a>.
FDA’s evolving CMC flexibility framework matters too. In January 2026, the FDA announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control requirements for cell and gene therapies, calling the changes helpful for expediting product development ahead of a Biologics License Application submission, according to the <a href=”https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation” target=”_blank” rel=”noopener”>FDA’s own guidance page</a>. A faster path to approval means more products moving through the supply chain sooner, which raises the bar on logistics readiness rather than lowering it.
IATA CEIV Pharma certification addresses the air cargo side of the equation. The program was created because, as IATA explains, the pharmaceutical industry relies on air transport for its speed, consistency and efficiency in ensuring high-value, time-sensitive, temperature-controlled products reach their destination safely, and certification confirms that facilities, equipment, operations, and staff meet the standards pharmaceutical manufacturers actually expect. Full details are available on <a href=”https://www.iata.org/en/services/certification/special-cargo/ceiv-pharma/” target=”_blank” rel=”noopener”>IATA’s CEIV Pharma program page</a>.
EU Good Distribution Practice and equivalent regional frameworks apply the moment a shipment crosses into international territory, layering documentation, storage, and transport requirements on top of whatever the origin country already demands. The <a href=”https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/good-distribution-practice” target=”_blank” rel=”noopener”>European Medicines Agency’s GDP guidance</a> sets out the wholesale distribution authorization and transport standards that any provider moving therapies into the EU needs to satisfy.
A provider that treats these as separate checkboxes rather than one integrated system will eventually create a gap somewhere in the chain. This is exactly the reasoning behind our own <a href=”https://stccouriers.in/expertise/regulatory-compliance/”>regulatory compliance</a> approach, which is built to satisfy FDA, EMA, and IATA requirements on a single shipment rather than treating each as an isolated hurdle.
What to Look for When You Choose a Cell and Gene Supply Chain Partner
By this point you already know the theory. Here is how to apply it when you are actually comparing vendors.
Validated Temperature Range Coverage
Ask for the exact ranges a provider supports and request their thermal validation data, not just a marketing claim. A partner should be able to demonstrate performance across cryogenic (-150°C to -196°C), frozen (-20°C to -80°C), refrigerated (2°C to 8°C), and controlled ambient (15°C to 25°C) bands, since a single therapy program often needs more than one of these across its lifecycle. This is the exact range our <a href=”https://stccouriers.in/expertise/cold-chain/”>cold chain</a> and <a href=”https://stccouriers.in/solutions/cryogenic-transportation/”>cryogenic transportation</a> services are built around.
Documented Chain of Custody and Chain of Identity
Every handoff, from apheresis unit to courier to manufacturing site and back, needs a documented record with a named individual signing at each step. Ask a prospective partner to walk you through their handoff protocol in detail. If the answer is vague, that is your answer.
Real-Time Monitoring With an Actual Response Plan
A data logger that records temperature is not the same as a monitoring system. The difference is what happens the moment a reading drifts outside range. Ask what the escalation path looks like, who gets notified, and how fast a courier can intervene before the excursion becomes unrecoverable. Our approach to <a href=”https://stccouriers.in/what-is-pharmaceutical-regulatory-compliance-in-cold-chain-shipping/”>pharmaceutical regulatory compliance in cold chain shipping</a> covers exactly this kind of accountability structure in more depth.
Validated Packaging, Not Generic Coolers
Passive shippers used for cell and gene products need thermal qualification testing under worst-case conditions, including realistic transit delays, not just best-case lab numbers. Our breakdown of <a href=”https://stccouriers.in/cold-chain-packaging-how-to-choose-a-solution-that-actually-protects-your-shipment/”>how to choose cold chain packaging that actually protects a shipment</a> covers what separates validated packaging from anything else on the market.
Global Reach With Direct-to-Patient Capability
Cell and gene therapy programs increasingly need shipments to move straight to a clinical site or, for some late-phase trials, directly to a patient’s home. A logistics network limited to major hub cities will not support this model. Look for a partner with an established footprint across a wide number of countries, with customs and permit handling built into the process rather than bolted on afterward.
Twenty-Four-Hour Human Support
Excursions and delays do not happen on business hours. A partner with a dedicated, always-available team is the difference between a resolved issue and a lost shipment.
How CFKR STC Couriers Manages the Cell and Gene Supply Chain
We built our cell and gene supply chain service around the exact gaps that cause most failures in this category.
Collection and transport. Our team collects directly from clinical sites, laboratories, and manufacturing facilities, keeping the product in temperature-controlled conditions from the first handoff. Every transfer is logged under a secure chain of custody system so nothing moves without a documented, traceable record.
Cryopreservation and storage. We maintain ultra-low temperature storage using liquid nitrogen between -150°C and -196°C, with backup systems in place to prevent deviations if equipment fails, and controlled access limiting who can handle stored material.
Global distribution. Our network spans more than 160 countries, working with established carrier partners to minimize transit time and reduce delay risk, including direct-to-patient and direct-to-clinical-site delivery where a program requires it.
Documentation and permits. We manage the full permit and documentation package for each shipment, covering FDA, EMA, and IATA requirements so your team is not chasing paperwork across three regulatory bodies on a single delivery.
If your program also touches conventional biologics or vaccines, our <a href=”https://stccouriers.in/solutions/pharmaceutical-supply-chain/”>pharmaceutical supply chain</a> and <a href=”https://stccouriers.in/solutions/lab-logistics/”>lab logistics</a> services run on the same infrastructure, which means one partner can cover your full portfolio instead of splitting it across multiple vendors.
Why This Decision Matters More Right Now
The volume moving through this supply chain is growing fast enough that logistics capacity is becoming a genuine bottleneck rather than an afterthought. The global cell and gene therapy market was valued at roughly USD 12.21 billion in 2025 and is projected to grow to USD 16.45 billion in 2026, expanding at a CAGR above 31 percent through the rest of the decade, according to <a href=”https://www.fortunebusinessinsights.com/cell-and-gene-therapy-market-114130″ target=”_blank” rel=”noopener”>Fortune Business Insights</a>. That growth is not evenly distributed. Analysts note the market is moving into a more disciplined growth phase, with demand increasing not only for scientific innovation but for the manufacturing, supply chain, and treatment-center capabilities needed to deliver these therapies at scale.
In plain terms, more approved therapies are entering the market at the same time more sponsors are competing for a limited pool of logistics providers who actually know how to handle cryogenic, chain-of-identity shipments. Locking in a capable partner now, before your program scales, is far easier than trying to switch providers mid-launch.
Common Mistakes Companies Make When Choosing a Provider
Sponsors frequently default to whichever courier already handles their standard pharmaceutical distribution, assuming cold chain experience transfers directly to cell and gene products. It does not. A provider comfortable with 2°C to 8°C refrigerated freight has no track record at -196°C, and the packaging, monitoring, and handling protocols do not scale down from one to the other automatically.
Another common mistake is underestimating documentation requirements until an audit exposes the gap. Chain of identity records, temperature logs, and customs permits need to exist in a retrievable, organized format from day one, not reconstructed after the fact when a regulator asks for them.
A third mistake is choosing based on price per shipment without factoring in the cost of a single failed delivery. Given what a lost autologous therapy shipment actually costs, in remanufacturing time, patient risk, and trial delay, the cheapest quote is rarely the cheapest outcome.
Making the Decision
If you are evaluating providers for a program moving into clinical trials, expanding into new markets, or scaling commercial supply, the questions above should form the backbone of your vendor assessment. A provider unwilling to answer them in specific, documented detail is telling you something important before you ever hand over a shipment.
Our team works directly with sponsors, CDMOs, and hospital systems to build a supply chain around the specific requirements of a given therapy program, rather than forcing every shipment through a generic pharma logistics template. You can review the full scope of our <a href=”https://stccouriers.in/solutions/cell-and-gene-supply-chain/”>cell and gene supply chain services</a> or <a href=”https://stccouriers.in/reach-out-to-cfkr-stc-couriers/”>contact our team directly</a> to talk through your specific shipping requirements, current pain points, and timeline.
Frequently Asked Questions
What temperature range do cell and gene therapy shipments require?
It depends on the product. Cryopreserved cell therapies typically ship between -150°C and -196°C using vapor-phase liquid nitrogen. Some gene therapy intermediates ship frozen between -20°C and -80°C, while certain formulations move refrigerated at 2°C to 8°C. A logistics partner needs validated capability across all of these ranges since a single therapy program can require more than one.
What is the difference between chain of custody and chain of identity?
Chain of custody tracks who physically handled a shipment and when. Chain of identity goes further, confirming that the exact patient-specific material has been correctly tracked and matched at every handoff. Autologous cell therapies require both, since a mix-up at any point could mean the wrong patient receives another patient’s manufactured cells.
Which regulations apply to cell and gene therapy logistics in the United States?
FDA 21 CFR Part 1271 governs human cells, tissues, and cellular and tissue-based products, covering donor eligibility and current good tissue practice requirements. Shipments involving biological substances also fall under IATA Dangerous Goods Regulations, and any international movement adds destination-country Good Distribution Practice requirements on top.
Why can’t a standard pharmaceutical courier handle cell and gene shipments?
Most standard pharma couriers are built around refrigerated ranges between 2°C and 8°C. Cell and gene products often need cryogenic or ultra-low temperatures far outside that range, along with chain-of-identity tracking and layered regulatory compliance that a general cold chain operation is not built to manage.
How do I evaluate a cell and gene supply chain provider before committing?
Request their validated temperature range data, ask how they document chain of custody and chain of identity at each handoff, confirm their regulatory certifications including IATA CEIV Pharma where relevant, and ask specifically what their escalation process looks like when a shipment shows a temperature excursion in transit.
Can cell and gene therapies be shipped directly to a patient’s home?
Yes, for some late-phase trials and approved commercial therapies, direct-to-patient delivery is becoming more common. This requires a logistics partner with a broad country footprint, established customs handling, and last-mile temperature-controlled capability, since the shipment can no longer rely on a hospital’s receiving infrastructure.